Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers.

ABSTRACT:

Introduction

Lecanemab was approved for early Alzheimer's disease in Japan, with ≈ 6000 patients treated in the first year post approval. This study explores real-world practices, challenges, and potential solutions.

Methods

We conducted an anonymized online survey of clinical specialists authorized to prescribe lecanemab, obtaining responses from 311 specialists who collectively treated 3259 patients with lecanemab.

Results

A majority of respondents (79%) reported wait times of ≤ 3 months from first consultation to initial infusion. One fourth reported tight outpatient space and staffing and significantly lower capacity of treatment than anticipated. Safety concerns were limited, with amyloid imaging-related abnormality-related interruptions in 3.5%. More than half h

SUBMITTER: Sato K 

PROVIDER: S-EPMC12536362 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature